Dr Reddy's up 3%, ITC drags 2%

Dr Reddy's Laboratories has entered into a strategic collaboration with Amgen, the biotechnology company, to market and distribute three Amgen medicines in India in the area of oncology and cardiology.

Under the terms of collaboration, the drug major will perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), Blincyto (blinatumomab) and Repatha (evolocumab) in India.

Kyprolis was approved by the US Food and Drug Administration in July 2015, in combination with lenalidomide and dexamethasone, for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.

Get Free Trial Service on Intraday Trading Tips , F&O tips Intraday Stock Tips,Stock Future Tips for 2 days on mobile for more details visit us http://www.marketmagnify.com/aboutus.php or call at 0731- 6619100.